Additional Study Information: A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including Fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation. The purpose of the study is to see if the combination of two drugs, cediranib and olaparib, is effective and tolerable in patients with ovarian cancer who have received at least 3 prior chemotherapy treatments, including treatment that included either carboplatin or cisplatin, and their disease came back within 6 months of the last dose of chemotherapy that included either cisplatin or carboplatin.